Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 8

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 8
---
ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx We Have a Strong Foundation for Growth Which Should Not Be Undervalued Invest in Our Innovative Pipeline and Commercial Opportunities Our CpG 1018 adjuvant – the backbone of our emerging pipeline – has the potential to provide a more tolerable vaccine for shingles, develop a plague vaccine in partnership with the US Department of Defense, and drive differentiated efficacy and improved product profiles in our Pandemic Influenza and Lyme Disease programs Protect and Build on Our Success of HEPLISAV - B Leverage our foundational commercial asset through growth and further gains in market share We expect to achieve at least 60% total United States market share by 2030 Leverage Our Proven Superior Commercialization Capability With HEPLISAV - B, Dynavax has demonstrated its ability to develop and commercialize effective vaccine candidates and compete effectively against established legacy products in the U.S. market © Copyright DYNAVAX 2025 9 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx (7.2)% (100)% (50)% 0 % 50 % 100 % 150 % 200 % 250 % May-2019 May-2020 May-2021 May-2022 May-2023 May-2024 62.4 % Source: Market data as of the filing date of our definitive proxy statement, 17 - Apr - 2025 1 Total stockholder return from 23 - May - 19, the date that DVAX announced its strategic pivot , to 17 - Apr - 2 025 , the date Dynavax filed its definitive proxy. 2 From FY 2020 to FY 2024. 3 From FY 2020 to FY 2024. 3 Net operating income from FY 2020 to FY 2024. 4 From YE 2020 to YE 2024 . 5 Based on 3 - month average at time of authorization. Our Strategy and Execution A re Increasingly Driving